Details

Autor(en) / Beteiligte

• Perdigão Neto, Lauro Vieira
• Oliveira, Maura Salaroli
• Orsi, Tatiana D’Annibale
• Prado, Gladys Villas Boas do
• Martins, Roberta Cristina Ruedas
• Leite, Gleice Cristina
• Marchi, Ana Paula
• Lira, Esther Sant’Ana de
• Côrtes, Marina Farrel
• Espinoza, Evelyn Patricia Sanchez
• Carrilho, Cláudia Maria Dantas de Maio
• Boszczowski, Ícaro
• Guimarães, Thais
• Costa, Silvia Figueiredo
• Levin, Anna S.

Titel

Alternative drugs against multiresistant Gram-negative bacteria

Ist Teil von

• Journal of global antimicrobial resistance., 2020-12, Vol.23, p.33-37

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Alternative antimicrobials should be considered to treat multiresistant Gram-negative bacteria (GNB).•Tigecycline, tetracyclines, ceftazidime/avibactam and fosfomycin are options for multiresistant GNB.•Chloramphenicol and quinolones do not perform well in multiresistant GNB. Enterobacterales and other non-fermenting Gram-negative bacteria have become a threat worldwide owing to the frequency of multidrug resistance in these pathogens. On the other hand, efficacious therapeutic options are quickly diminishing. The aims of this study were to describe the susceptibility of 50 multiresistant Gram-negative bacteria, mostly pan-resistant, against old and less-used antimicrobial drugs and to investigate the presence of antimicrobial resistance genes. A total of 50 genetically distinct isolates were included in this study, including 14 Acinetobacter baumannii (belonging to ST79, ST317, ST835 and ST836), 1 Pseudomonas aeruginosa (ST245), 8 Serratia marcescens and 27 Klebsiella pneumoniae (belonging to ST11, ST340, ST258, ST16, ST23, ST25, ST101, ST234, ST437 and ST442). The isolates were submitted to antimicrobial susceptibility testing and whole-genome sequencing to evaluate lineages and resistance genes. Our results showed that some strains harboured carbapenemase genes, e.g. blaKPC-2 (28/50; 56%) and blaOXA-23 (11/50; 22%), and other resistance genes encoding aminoglycoside-modifying enzymes (49/50; 98%). Susceptibility rates to tigecycline (96%) in all species (except P. aeruginosa), to minocycline (100%) and doxycycline (93%) in A. baumannii, to ceftazidime/avibactam in S. marcescens (100%) and K. pneumoniae (96%), and to fosfomycin in S. marcescens (88%) were high. Chloramphenicol and quinolones (6% susceptibility each) did not perform well, making their use in an empirical scenario unlikely. This study involving genetically distinct bacteria showed promising results for tigecycline for all Gram-negative bacteria (except P. aeruginosa), and there was good activity of minocycline against A. baumannii, ceftazidime/avibactam against Enterobacterales, and fosfomycin against S. marcescens.